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KAJIAN EXPLORATIF MENGKAJI FAKTOR-FAKTOR BERKAITAN 
DENGAN MASA MULA DAN KETERUKAN NEUTROPENIA  
DI KALANGAN PESAKIT KANSER   
 
ABSTRAK  
 
 
         Neutropenia ialah satu keadaan apabila kandungan neutrophil dalam darah 
menjadi kurarg daripada 1500 sel/ µl dan ianya merupakan satu kesan sampingan biasa 
akibat kemoterapi kanser. Selain dikaitkan dengan mobiditi dan mortaliti yang agak 
tinggi, neutropenia juga dapat menyebabkan pengurangan dos atau penangguhan 
rawatan kemoterapi yang mungkin mempunyai kesan tidak baik keatas kualiti kehidupan 
pesakit kanser dan dapat menyebabkan peningkatan beban ekonomi. Masa mula 
neutropenia sering berlaku selepas kitaran pertama kemoterapi kanser kerana 
kebanyakan kemusnahan sum-sum tulang berlaku selepas kitaran pertama iaitu pada dua 
minggu pertama pemberian kemoterapi. Keterukan neutropenia diklaskan sebagai 
neutropenia ringan apabila kiraan neutrofil absolut (ANC) turun antara 1500 dan 1000 
sel/ µl; neutropenia sederhana apabila ANC antara 1000 dan 500 sel/ µl dan neutropenia 
teruk apabila ANC kurang daripada 500 sel/ µl. Objektif utama kajian ini ialah untuk 
mengenalpasti faktor-faktor risiko utama yang mempunyai hubungan dengan masa mula 
dan keterukan neutropenia serta untuk menentukan rawatan neutropenia yang sering 
digunakan. Satu kajian pemerhatian retrospektif yang menggunakan persampelan mudah 
telah dijalankan ke atas pesakit tumor pejal yang dimasukan ke Hospital Pulau Pinang di 
antara tahun 2003 hingga 2006. Sebanyak 4503 rekod pesakit dalam tempoh ini telah 
diperiksa dan didapati hanya 117 sahaja yang memenuhi kriteria penyertaan. Data 
demografik pesakit, jenis diagnosis kanser, data pemberian kemoterapi, data 
xx 
 
neutropenia, data makmal dan data rawatan telah dikumpulkan dengan menggunakan 
borang pengumpulan data. Ujian-ujian statistik inferensial bersesuaian iaitu ujian Chi-
square dan ujian Fisher’s Exact telah digunakan bagi menganalisakan data-data yang 
dikumpul. Bagi variabel-variabel yang menunjukkan hubungan signifikan, Logistic 
Regression (Multinomial Logistic Regression) telah digunakan bagi menentukan faktor 
utama yarg mempunyai hubungan dengan masa mula dan keterukan neutropeneia. 
Keputusan kajian ini menunjukkan kebanyakan neutropenia berlaku di kalangan kuam 
wanita (73.5%) berbangsa Cina (70.1%) dan berumur di antara lingkungan 50 hingga 59 
tahun (39.3%). Walau bagaimanapun, data-data demografik ini bukan merupakan faktor 
risiko bagi masa mula dan keterukan neutropeneia. Neutropenia sering berlaku di 
kalangan pesakit kanser payu dara (64.1%) tetapi tiada hubungan signifikan diperolehi 
antara jenis kanser yang di diagnosiskan dengan masa mula dan keterukan neutropenia. 
Gabungan siklofosfamid, epirubisin dan 5-flurourasil (40.2%) adalah regimen yang 
paling banyak digunakan tetapi masih terdapat hubungan yang tidak signifikan antara 
kemoterapi dengan masa mula dan keterukan neutropenia. Didapati kebanyakan pasakit 
mula mengalami neutropenia selepas dua minggu administrasi kemoterapi (84, 71.8%) 
yang bermaksud bahawa neutropenia berlaku selepas kitaran pertama kemoterapi. Juga 
didapati kebanyakan pesakit neutropenia mengalami neutropenia ringan (43, 36.8%) dan 
neutropenia sederhana (41, 35%). Terdapat hubungan signifikan antara pusingan 
pertama kemoterapi dengan masa mula neutropenia tetapi hubungan adalah tidak 
signifikan dengan keterukan neutropenia. Hubungan signifikan wujud antara demam 
dengan keterukan neutropenia. Tambahan lagi, hipotensi dan pening kepala adalah dua 
tanda klinikal utama yang menunjukkan hubungan signifikan dengan keterukan 
neutropenia. Bakteria gram-negatif adalah penyebab utama jangkitan di kalangan pesakit 
xxi 
 
neutropenia yang dikaji. Filgrastim adalah rawatan utama dan diikuti oleh gabungan 
filgrastim dan ceftazidime bagi mengatasi keterukan neutropenia serta merawat 
jangkitan yang berkaitan. Oleh demikian, kajian ini menunjukkan pusingan pertama 
kemoterapi adalah faktor risiko yang mempunyai hubungan dengan masa mula 
neutropenia. Manakala demam, sakit kepala dan hipotensi adalah faktor-faktor risiko 
yang mempunyai hubungan dengan keterukan neutropenia. Filgrastim adalah rawatan 
yang paling biasa digunakan.   
 
Katakunci: Masa mula neutropenia, Keterukan neutropenia, Kajian pemerhatian 
retrospektif, Kemoterapi, Demam, Tanda klinikal, Rawatan neutropenia.           
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AN EXPLORATIVE STUDY ON FACTORS ASSOCIATED WITH 
NEUTROPENIA ONSET AND SEVERITY AMONG CANCER  
PATIENTS 
 
 
ABSTRACT  
 
 
 Neutropenia is a decreased in the absolute number of neutrophils in the blood to 
less than 1500 cell/ µl and is a common side effect of cancer chemotherapy. Apart from 
being associated with considerable morbidity and mortality, neutropenia could also 
result in the dose reduction or a delay in chemotherapy courses that could have a 
detrimental effect on cancer patients quality of lives and could cause a considerable 
economic burden. Neutropenia onset mostly occurred after the first cycle of cancer 
chemotherapy since the major bone marrow destruction happened after the first cycle i.e. 
within the first two weeks of chemotherapy administration. Neutropenia severity is 
classified as mild neutropenia when the absolute neutrophil count (ANC) drops between 
1500 and 1000 cell/ µl, moderate neutropenia when ANC falls between 1000 and 500 
cell/ µl and severe neutropenia when ANC falls below 500 cell/ µl. Thus the main 
objective of this study is to identify the main risk factors associated with the onset and 
severity of neutropenia and to determine the most common treatment used for 
neutropenia. An observational retrospective study using convenient sampling was 
carried out on solid tumor patients admitted to Penang Hospital between 2003 and 2006. 
A total number of 4503 patients files during this period were reviewed and 117 were 
found to fulfilled the inclusion criteria. Patient’s demographic data, type of cancer 
diagnosis, chemotherapy administrated data, neutropenia data, laboratory data and 
treatment data were collected into data collection form. Appropriate inferential statistics 
tests were used to analysed the data collected which were Chi-square test and Fisher’s 
xxiii 
 
Exact test. As for the variables that showed a significant association, Logistic 
Regression (Multinomial Logistic Regression) was used to find the main risk factor 
associated with onset and severity of neutropenia. The result of this study showed that 
neutropenia occurred more in the female (73.5%), in the Chinese (70.1%) and between 
the age of 50-59 years old (39.3%). However, the demographic data was found not to be 
a risk factor for neutropenia onset and severity. Neutropenia seems to occur mostly in 
breast cancer patients (64.1%) but there was no significant association between types of 
cancer diagnosed and neutropenia onset and severity. Combination of 
cyclophosphamide, epirubicin and 5-flurouracil (40.2%) was the most frequent regimen 
used but again there was no significant association between the chemotherapy and 
neutropenia onset and severity. It was found that most of the patients started to develop 
neutropenia after two weeks of chemotherapy administration (84; 71.8%) which means 
that neutropenia occurred after the first cycle of chemotherapy. Also it was found that 
most of the neutropenic patients suffered mild (43; 36.8%) to moderate neutropenia (41; 
35%). There was a significant association between the first cycle of chemotherapy and 
neutropenia onset but an insignificant association was seen with neutropenia severity. 
Significant association existed between fever and severity of neutropenia. In addition the 
two major clinical signs that showed significant association with neutropenia severity 
were hypotension and headache. Gram-negative bacteria was found to be the 
predominant cause of infection among the neutropenic patients studied. Filgrastim is the 
major type of treatment used followed by filgrastim plus ceftazidime combination to 
overcome neutropenia severity and infection associated with it. Thus this study showed 
that the first chemotherapy cycle is a risk factor associated with neutropenia onset. 
Where as fever, headache and hypotension are complication and risk factors associated 
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with neutropenia severity. Filgrastim was the most common treatment used. So it is a 
very important to take special supervision for cancer patients especially after first cycle 
of chemotherapy which consider the most dangerous risk factor for neutropenia onset. 
The uses of filgrastim (Neupogen®) should be emphasized beside accurate calculation 
for chemotherapy doses. Emphasize on doing laboratory tests (i.e., for neutrophil count), 
keep monitoring for body temperature before and after chemotherapy cycle. Emphasize 
on doing culture and sensitivity tests and there must be no delay in administration of 
empirical antibiotic therapy especially with a wide range antibiotic therapy like beta-
lactam antibiotic until the culture and sensitivity test appear.         
 
Keywords: Neutropenia onset, Neutropenia severity, Observational retrospective study, 
Chemotherapy, Fever, Clinical signs, Neutropenia treatment.    
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CHAPTER 1 
INTRODUCTION 
 
 
1.1 White Blood Cells and Neutrophil  
            Neutrophil is the major type of white blood cell (WBC) which form part of the 
whole blood. They are also called polymorphonucleat leucocytes or granulocytes and 
represent about 45 % - 70 % of the total WBC (Walker and Edwards, 2003; Dale, 2005). 
They are synthesized and produced from the hematopoietic stem cell that is found in the 
bone marrow and it required 10-14 days for hematopoietic stem cell to produce mature 
neutrophils (Dale, 2004; Dale, 2005). Neutrophils are considered as the main defense 
mechanism of the body innate host defense system since they will protect the body from 
invasion of micro-organisms (Dale, 2004). Neutrophils act as phagocytes and get rid of 
bacterial, fungal, germs or any foreign body in the blood (Frey, 1999). Neutrophil’s 
cytoplasm also contains granules, for which they are also called granulocytes. These 
granules contain glycogen and antibacterial substances (Dale, 2005). Neutrophils have a 
very short life span that is only for 6-10 hours but during inflammation or infection 
neutrophils will migrate to the inflamed tissues, exert their phagocyte action and remain 
active there for about 2-6 days (Dale, 2005; Frey, 1999). Neutrophils have receptors on 
their surfaces that will help them to contact and bind to the tissues and vascular 
endothelial that lie beside or near the problem or infection or inflammation sites (Dale, 
2005).  
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1.2 Definition of Neutropenia 
            Neutropenia is defined as a decrease in the absolute number of neutrophils in the 
blood. Clinically, neutropenia is defined as a decrease in the absolute neutrophil count 
(ANC) of more than two standard deviations below the normal range. So the patient is 
considered as neutropenic when the ANC is lower than the normal level which is 1500 
cell/ µl (Dale, 2005).   
            So generally this dangerous condition called neutropenia will occur when the 
neutrophils cells counts is lower than the normal count which is 1500 cell/ µl (Dale, 
2005; Walker and Edwards, 2003; Frey, 1999; Frey and Granger, 2002; Linker, 2000). 
Even so when the neutrophil count is more than 1000 cell/ µl there will still be normal 
protection against infection. When the level of neutrophils falls to 500-1000 cell/ µl it is 
classified as mild neutropenia and moderate neutropenia happened when the count falls 
between 200-500 cell/ µl (Dale, 2005; Frey, 1999; Frey and Granger, 2002). When the 
neutrophil count falls lower than 200 cell/ µl it is considered as a very serious condition 
that requires the patient to be admitted to the hospital and treated with antibiotics (Frey, 
1999; Frey and Granger, 2002). It has been reported that the normal neutrophil count in 
the white man is 1500 cell/ µl while in the black man the normal is lower (i.e., 1200 cell/ 
µl) (Linker, 2000).  
 While febrile neutropenia (i.e., when patient developed fever) is mostly associated 
with chemotherapy regimen it may also occur after irradiation of most parts of the bone 
marrow. Here the term febrile neutropenia is usually used to describe the occurrence of 
neutropenia and fever that is when the body temperature is ≥ 38.3˚C or oral temperature 
≥ 38˚C for more than one hour and the neutrophil count is ≤ 500 cell/ µl or it will reduced 
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to ≤ 500 cell/ µl within the next 48 hours (Bledsoe, et al., 2005; Dale, 2005; AL-Ahwal, 
2005; Lyman and Wilmot, 2006).  
 
 
1.3  Overview of Neutropenia  
            There are many studies on neutropenia which looked at the mechanism of 
neutropenia occurrence, the problems that may occur due to neutropenia, the treatment of 
neutropenia and the management of neutropenia in order to save patients life.    
            The study by Nwakoby et al. (2001) showed that neutrophilia is most commonly 
seen in patients who suffered from either infection or inflammation. The neutrophil cells 
will be the first cells arriving at the sites of damage or problem. Approximately 100 
billion neutrophils could be produced during one day. Thus neutrophils are considered as 
the major defense mechanism. Figure 1.1 shows the action of neutrophil as a phagocyte.   
 
                Figure 1.1: The neutrophil cell act as phagocyte which is the major 
                defense mechanism (Bolyard et al., 2001). 
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            So when an inflammation occurs or take place this will lead to a direct or indirect 
stimulation of the bone marrow which will lead to an increase in the number of 
neutrophils in the blood. The mature neutrophils will live for a short period of time (i.e., 
6-10 hours) and then they will die by a process called apoptosis. But there are some 
factors that will lead to an increase in the life span of the neutrophil cells which include 
granulocyte-colony stimulation factor (G-CSF), granulocyte-macrophage colony 
stimulation factor (GM-CSF), interleukine-2, gamma interferon, tumor necrosis factor 
(TNF) and glucocorticoids. While on the other hand there are some materials like nitric 
oxide generations both endogenous and exogenous will destroy the neutrophils or 
stimulate neutrophil apoptosis (Nwakoby et al., 2001). This is shown in Figure 1.2 
below:  
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Figure 1.2: The apoptosis process: picture A shows normal blood while picture B 
shows apoptosis which lead to neutropenia (Nwakoby et al., 2001).  
                                
                               
                               
 
 
 
 6
1.4  Adverse Effect of Neutropenia   
            The incidence of neutropenia has been shown to have negative effects on the 
patient. The percentage of cancer patients who did not receive their total amount of 
chemotherapy drug doses has increased. Fifty percent (50%) of these cancer patients 
received less than 85% of the actual doses because of neutropenia. Breast cancer seems to 
be the type of cancer most associated with neutropenia complication. About 25% of the 
breast cancer patients suffered from neutropenia resulting in reduction of their 
chemotherapy doses (Lyman and Wilmot, 2006).    
            The study by Ashley et al. (2004) in USA clearly described the effect of 
neutropenia on quality of life. Thirty-four (34) neutropenic patients developed grade 4 
neutropenia after being administered myelosuppressive chemotherapy at days 21 or 28 of 
the first cycle. Their neutrophil counts were assessed on days 7, 10, 14, 21 and 28 of the 
chemotherapy cycle. Each patient with neutrophil counts lower than 1.5 × 109 cell/ L was 
interviewed by the researchers. The questions were concerned with the effects of 
neutropenia which include physical feelings and sensations, interactions with others, 
daily activities, financial impact, sex life, ability to work, satisfaction with medical care, 
emotions and many others aspects of quality of life. The results of this study showed that 
neutropenia has a dramatic effect on the patient life and fatigue was the predominant 
characteristic. Patients described fatigue as feeling weak, exhausted and tired. 
Psychological problems were also reported by the patients, such as sadness, anxiety, 
reduce self-worth and inability of fulfilling normal roles. These results hence showed that 
neutropenia as a result of chemotherapy do effect patient’s quality of life.  
            Another study conducted also in USA by Ropka and Faan (2007) examined the 
effect of neutropenia on patient’s life. The result of this study also showed that the 
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occurrence of neutropenia has a detrimental effect on the patient’s life. These detrimental 
effects like fatigue considered as the most common side effect, that lead to a decreased in 
their ability to perform the daily life activities. Also decreased and delayed in 
chemotherapy treatment had lead to increased in cancer cell growth and tumor size. This 
will lead to serious side effects on patients lives that may lead to their death.    
 
1.5   Neutropenia Incidence and Prevalence   
            Neutropenia is a common side effect of cancer chemotherapy and will occur or 
take place in one out of three patients who received chemotherapy. Once neutropenia 
happens chemotherapy should be delayed in order to give the body a chance for 
producing new neutrophils (Neutropenia Association Inc. 1993). There are no or very few 
studies that give an exact number of neutropenia prevalence but some studies only 
mentioned it as a common side effect. It has also been considered by some as a common 
and major complication which will threaten the patients lives and reduced or delay the 
chemotherapy doses (Di Maio et al., 2005; Fortner et al., 2005; Gabrilove, 2005; 
Timmer-Bonte et al., 2005). While studies by the Neutropenia Association Inc and 
European Council for Rare Diseases considered severe chronic neutropenia, cyclic 
neutropenia, idiopathic neutropenia and autoimmune neutropenia as rare diseases 
especially the severe chronic neutropenia. However, there was no accurate number or 
percentage of neutropenia prevalence or occurrence as a side effect of chemotherapy was 
reported (Neutropenia Association Inc. 1993 and The European Parliament and the 
Council of the European Union, 1999). While Munshi (2000) mentioned in his study that 
neutropenia is a common side effect most often due to chemotherapy treatment but on the 
other hand severe neutropenia occurrence is uncommon, but it can cause serious 
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mortality and morbidity as a result of infection associated with it. He also mentioned that 
epidemiological studies showed a wide variation in the occurrence of neutropenia 
according to geographical regions such as the average occurrence of neutropenia in the 
USA is 56.4 case per million people.  
 
1.6  Neutropenia Diagnosis  
           The diagnosis of neutropenia is made by performing the following tests:  
 
1.6.1  Blood Count Monitoring  
            The first test to investigate the suspicion of neutropenia presence is to perform 
complete blood count (CBC) or full blood count (FBC) where by them neutrophil 
numbers will be measured. If the results showed a low neutrophil count then these tests 
will be repeated in order to be certain that neutropenia is actually present (Bolyard et al., 
2001).      
 
1.6.2 Bone Marrow Aspirate / Trephine Biopsy    
            After performing blood test a bone examination could be carried out to confirm 
the results. Bone marrow biopsy is done by obtaining bone marrow aspirates from 2 sites 
that is from the middle of the bone and also from solid bonier part of the bone. This bone 
biopsy is performed with patient under general anesthesia or local anesthesia with 
sedation. These bone marrow samples are usually taken from the large bones such as 
large pelvic bone, the ilium, or sometimes from the flat breastbone (i.e., the sternum) 
(Bolyard et al., 2001).  
 
 9
1.7  Neutropenia Causes  
            Factors that play a major role in causing neutropenia are demographic factors, 
hematological disorder, autoimmune diseases, infection, drugs reactions and 
chemotherapy or radiotherapy (Dale, 2005; Frey and Granger, 2002; Lyman and Wilmot, 
2006). 
  Neutrophils production decrease in the elderly since they have a lower ability to 
produce mature neutrophils than younger people. Besides that the neutrophil count in 
white man is higher than that in the black man. Also neutropenia incidence seems to be 
more in women than men (Dale, 2005; Frey and Granger, 2002; Linker, 2000).     
            Hematological diseases like leukemia, myelodysplastic syndrome, Hodgkin’s and 
non-Hodgkin’s diseases and multiple myloma have been shown to cause neutropenia 
(Dale, 2005). In these hematological diseases severe destruction of bone marrow leads to 
destruction of stem cells. This will result in the prevention or decrease in neutrophils 
production and thus causing neutropenia (Dale, 2005). Also there is an effect on red 
blood cells (RBC) and platelets production which will lead to severe anemia and 
thrombocytopenia. Usually the patient will suffer from fever ≥ 38.5˚C as well as 
gingivitis, bleeding, stomatitis, bone chills and patient might also collapse (Verstraete et 
al., 1997). 
 Neutropenia has also been associated with autoimmune disease like systemic 
lupus erythromatosis (SLE). The neutropenia in SLE is usually mild and the patient may 
not suffer from serious bacterial infection. However patients with SjÖren syndrome and 
rheumatoid arthritis may have severe neutropenia so they are at higher risk of bacterial or 
fungal infection. Neutropenia may also occur with aplastic anemia (Dale, 2005). 
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 Many drugs such as diuretics, chlorpromazine, and allopurinol have been shown 
to cause neutropenia. Two mechanisms have been suggested to cause neutropenia. 
Firstly, the drug produce dose dependant toxicity on cell production, protein synthesis, 
bone marrow and cell survival. Secondly, the mechanism may involve the drug inducing 
immunological reactions. For an example the binding of drugs with the surface of the 
neutrophil cell will lead to cell destruction and cause production of neutropenia. These 
two mechanisms are not always seen but happen only in a small percentage of the 
patients. Also these two mechanisms need a long duration of use that is from starting the 
administration of the drug to the appearance of neutropenia (Dale, 2005). 
 While in the case of solid tumor as the focused of this present study, most of the 
patients have normal neutrophils but due to the intensive chemotherapeutics drugs and 
regimens neutropenia developed (Rolston, 2001). 
Neutropenia has been seen to be mostly associated with cancer chemotherapy and 
radiotherapy. These chemotherapeutic drugs will effect the production of folic acid as 
well as the synthesis of DNA, RNA and protein by acting as anti metabolite which will 
lead to bone marrow destruction (Frey, 1999; Dale, 2005; Frey and Granger, 2002; 
Linker, 2000; Verstraete et al., 1997). Bone marrow destruction will then lead to a 
decrease in neutrophil cell production. Due to this, the chemotherapy and radiotherapy 
are considered as the main causes for neutropenia or febrile neutropenia (i.e., neutropenia 
when associated with fever and ANC ≤ 500 cell/ µl). Also these chemotherapeutic drugs 
will kill and suppress every cell that is highly dividing or actively growing like cancer 
cell but unfortunately they also have an effect on the blood cells especially bone cells and 
neutrophil cells (Fortner et al., 2005).  
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Examples of chemotherapeutic drugs which are highly associated with neutropenia are 
actinomycin, asparaginase, cytarabine, busulfan, cisplatin, daunorubicin, etoposide, 
fluorouracil, ifosfamide and methotrexate (Dale, 2005; Linker, 2000; kimble-koda, et al., 
2002).  
 
1.7.1 Neutropenia and Demographic Factors  
            There are studies indicating that there is a relationship between age, ethnic group 
and gender of the patient with neutropenia induced as a side effect of chemotherapy drug 
use (Dale, 2004; Frey and Granger, 2002). 
 A study that was done by Wolff et al. (2005) in the USA looked at the risk factors 
including gender associated with neutropenia and the development of its complication. 
The study was a prospective study on 2,222 patients. Eight hundred and eighty six (886) 
or 40% of these patients were 65 years old or older. The results of the study showed that 
there was a significant association relationship between severity of neutropenia and 
gender (P= 0.001). A significant relationship between neutropenia complications and 
gender (P= 0.004) was also obtained. In their study, 66.5% of the total patients were 
female and 33.5% were male. Thus it seems that female suffered from neutropenia much 
more than male.   
 
1.7.2 Neutropenia and Solid Cancer   
            Neutropenia has been shown to be associated with solid tumor especially breast 
cancer where by about 25% of them developed neutropenia. However this association 
seems to happen with the use of specific chemotherapeutic drugs or regimens (Dale, 
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2004). There are very few studies which focused on the causative factors of neutropenia 
in solid cancer.  
            A study by Koasak et al. (2002) in USA looked at the differences between the 
occurrence of fever and neutropenia in pediatric patients with solid cancer and leukemia. 
Two hundred and eighty three (283) pediatric febrile neutropenic pediatric patients were 
enrolled in the retrospective study. Thirty eight percent (38%) of the patients had 
leukemia and 62% had solid tumors. The results showed that fever of unexplained origin 
developed in 73% of the leukemic patients and 74% of the solid tumor patients. The 
median duration for neutropenia in leukemic patients was 9 days while in solid tumor 
patients was 7.5 days. Both were significant with P <0.0002. Severe neutropenia with 
ANC < 100 cell/ µl was present in 75% of leukemic patients verses 70% of patients with 
solid tumor. But there was no significant association between severity with both solid 
tumor and leukemia. So Koasak et al found that there was a significant association 
between cancer type and neutropenia duration, but there was no significant association 
between the cancer type and severity of neutropenia.     
           A second study looking at the relationship between solid tumors and neutropenia 
severity and risk factors was done by AL-Ahwal (2005) in Kingdom Saudi Arabia 
(KSA). A total number of 56 solid cancer patients suffering from febrile neutropenia 
were studied in order to obtain the association. Those patients consisted of 38.2% male 
and 67.2% female. Looking at the age, 61.2% of them were less than 50 years old while 
38.8% were more than 50 years old. The duration of neutropenia was less than 7days in 
92.5% and 7-14 days in 7.5% of the patients. None of the patients experienced 
neutropenia more than 14 days. The results of the study showed that the association of 
neutropenia duration with solid tumor was insignificant (P= 0.081). The results also 
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showed that only 16.4% of patients suffered from severe neutropenia with ANC < 100 
cell/ µl. The association between the severity of neutropenia both with ANC higher than 
or lower than 100 cell/ µl and solid tumor were insignificant since P= 0.692 for Chi-
square test and Fisher’s Exact test. Looking at the risks factors, the results showed that 
the association between severity of neutropenia and solid tumor was not significant but 
the association of co-morbidity of chemotherapy and solid cancer was significant. 
 
1.7.3  Neutropenia and Chemotherapy Drugs and Cycles  
            Many studies showed neutropenia as the negative result of the use of 
chemotherapeutics drugs. Neutropenia occurrence or onset is mainly and highly 
associated with the first cycle of the chemotherapy more than the others or subsequent 
cycles. Chemotherapeutic drugs will cause the depletion of the bone marrow which will 
lead to the reduction in the production of the neutrophils and consequently lead to 
neutropenia. In addition neutropenia severity will also increase because of these 
chemotherapeutics drugs (Kern, 2001). 
Figure 1.3 shows the highly dividing cells that could be depleted because of the effect of 
chemotherapy.    
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             Figure 1.3: The highly dividing stem cell that all the blood cells are 
             derived from (Bolyard et al., 2001).   
 
 
 
            The study by Di Maio et al. (2005) produced an interesting result where by the 
effect of the chemotherapeutic drugs were clearly shown. The total number of patients 
involved in this study was 1265. The patients were classified into two groups. The first 
group consisted of 436 patients and were given all the chemotherapeutics drugs used in 
the experiment. The types of chemotherapeutics drugs used were gemcitabine, cisplatin 
and vinorelbine and these drugs were used in different trials. These patients were called 
“inland markers” since they were still living after receiving all the different types of 
chemotherapies over 180 days. The second group of 829 patients did not receive any of 
the chemotherapeutics drugs and were called “out of land markers”. The main result 
produced by this study was the ratio of the living for those inland markers patients who 
suffered from mild neutropenia was 0.74 of the whole cases. While for those patients who 
suffered from severe neutropenia the ratio of death was 0.65 of the total cases. Thus this 
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study emphasized that the correct doses of chemotherapeutics drugs must be used in 
order to prevent the incidence of lethal neutropenia.  
            Chemotherapy as an important risk factor for neutropenia occurrence and severity 
was also supported by Friese (2006) who reported that neutropenia was the major 
hematological toxicity induced by the cancer chemotherapy. This would thus lead to 
dangerous conditions such as life threatening infection.   
 While in USA a study conducted by Wolf et al. (2005) on 2,222 cancer patients 
showed that 1/3 of them (733) received fewer than 4 cycles of the chemotherapy because 
of chemotherapy complications. The most important result obtained was that half of the 
neutropenia events occurred within the first cycle of chemotherapy especially among the 
breast cancer patients.  
            .          
1.8  Neutropenia Stages and Source of Infection  
 Neutropenia stages encompass the period of neutropenia as well as its association 
with infections. These infections are the results of immunosuppression which could 
involve bacterial, fungal or even viral infections (Greene, 2004). Neutropenia levels and 
stages that developed in cancer patients depend on the chemotherapeutics drugs they 
received (Agaliotis, 2004). Neutropenia stages and its main source of infection will be 
emphasized below.  
 
1.8.1 Neutropenia From Day 0-7  
 This period of neutropenia involve the appearance of bacterial infection arising 
from the gastro-intestinal track (GIT) or the skin. The most important factor that will lead 
to this bacterial infection is the high use of improper antibiotics which will lead to the 
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production or occurrence of bacteremia. This happens because of the suppression of 
gram-positive bacteria which would lead to the occurrence of gram-negative infection 
and this later lead to bacteremia (Greene, 2004).   
 
1.8.2 Neutropenia From Day 7-14 
In the second week of neutropenia the occurrence of bacterial infection is still 
mainly originate from the GIT which is again the primary source of bacteria. Also with 
the improper use of antibiotics, this would cause a lack of the aerobic gram-positive and 
gram-negative bacteria. This would thus result in the anaerobes and the yeast to become 
the main cause of infection. All of these will lead to the increase in the growth of candida 
in the GIT and will result in candidemia which is a new risk for the patient. The main 
signs of candida infection are fever, headache and chills within 2 hours. After 3 hours the 
candida infection will move from the GIT to the blood stream as well as to the urinary 
tract. This type of candida infection will colonize the GIT and is considered as a common 
infection in neutropenic patients especially after two weeks of neutropenia occurrence 
(Greene, 2004).  
 
1.8.3 Neutropenia After Two Weeks or More  
            This period is the most dangerous and serious period for both clinicians and 
patients. At this time the clinicians would be trying to protect and prevent the patient 
from being infected. As for the patients, this is a critical and dangerous period because 
they are very prone to infections. During this period, beside GIT and the skin the 
endogenous infection sources now involved the respiratory tract. Also the hospital 
environment and the hospital staff are considered as an exogenous source of infection and 
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play an important role in patients infections. Viral infection caused by BK virus, Herpes 
simplex and Varicella zoster are now becoming a dangerous factor. An important 
characteristic of this period is that occurrence of bacterial resistance towards antibiotics. 
This is especially seen among gram-negative bacteria like Escherichia coli and 
Pseudomonas aeruginosa which are mostly resistance to various types of antibiotics. The 
main causes for anaerobic infection at this stage are Clostridium species and 
Fusobacterium specie. While for the fungal infection they are also of the resistant types 
such as Candida albicans species which is resistant to fluconazole (Greene, 2004).   
                    
1.9       Neutropenia, Fever, Clinical Signs and Infection Types    
1.9.1 Neutropenia and Fever   
            The occurrence of fever in neutropenic patients is an indication of the presence of 
infection. When a neutropenic patient has ANC ≤ 500 cell/ µl and the oral temperature ≥ 
38.3˚C or ≥ 38˚C over one hour minimally then the patient is suffering from febrile 
neutropenia. When fever is present then 15%-20% of these fever are associated with 
bacteremia primarily and fungal infection as the secondary infection (Flaherty, 1999).      
            In case of severe neutropenia the patients will show two main characteristics 
which are firstly fever and secondly one of the signs of infection such as gingivitis, 
abdominal pain which resulted because of liver infection, kidney infection and 
pneumonia (Flaherty, 1999; Frey, 1999). 
            There are many studies which focused on fever and neutropenia such as the study 
by Zia Rahman et al. (1997) in USA on 174 breast cancer patients. The median age of the 
patients was 54 years (29-74 years) and they received a total of 610 chemotherapy 
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courses. The median number of the chemotherapeutics courses received was 3 (range 1-
17 courses). One of the aims of his study was to look for the relationship between fever 
and ANC. The results showed that the association of fever with neutropenia was not 
significant until ANC is less than 500 cell/ µl (P< 0.01).           
 Klastersky (2004) in Belgium showed that 10%-50% of fever occurred with solid 
tumor and 80% with blood malignancy. In this study it was mentioned that the fever 
happened as a complication of the chemotherapy drug used and it required 7 to 12 days of 
treatment.   
            Another retrospective study by Ammann et al. (2004) in Switzerland was carried 
out on 132 febrile neutropenic patients. In their study, fever associated with neutropenia 
was a result of chemotherapeutics drugs used and 20%-55% of the fever was because of 
bacterial infection. Thus empirical antibiotic used was important. The main conclusion of 
their study was that the increased in the occurrence of febrile neutropenia is associated 
with the increased in the chemotherapy intensity. They also recommended that 
modification of the first line antibiotics treatment was not necessary because this will 
lead to change in the resistance pattern of bacteria.     
            Another study by Jenson (2003) in USA highlighted that fever and neutropenia 
were the major complications of the use of chemotherapeutics drugs. Fifty years ago 
mortality due to these complications was very high (80%) however at present the 
mortality rate has reduced to lower than 20%. They also reported that the incidence of 
fever and neutropenia was very high in patients who received intensive chemotherapy. 
Apart from infection (bacterial), fever in neutropenic patients can be caused by pyrogenic 
medications, blood transfusion as well as allergic reactions.    
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1.9.2 Neutropenia and Clinical Signs 
 Signs and symptoms associated with neutropenia are usually subtle, but fever 
remains the main and the most important sign considered as an indication of early 
infection (Talcott and Rubenstein, 2001). The presence of these clinical signs usually 
occurs in those patients who were treated with chemotherapy drugs that could lead to 
severe neutropenia. These signs are considered as a result of severe neutropenia since 
patients with severe neutropenia have been shown to develop problem and infections of 
the liver, kidney and chest (pneumonia) as well as oral mucositis and rectal ulcer. The 
occurrence of bacterial, fungal or even viral infections among severe neutropenic patient 
is very high thus this would lead to the clinical signs and fever (Dale, 2004; Frey and 
Granger, 2002; Schimpff, 2001).   
 One study conducted by Munschi (2000) in the USA suggested that it is very 
important that the physician must focus on the signs and symptoms associated with 
severe neutropenia. Also this study indicated that any neutropenic patients with ANC < 
500 cell/ µl and with the presence of fever and signs of infection need immediate 
hospitalization. While those who were classified as mild neutropenic patients without 
fever and signs of infection just need monitoring of the blood count several times per 
week for 6 to 8 weeks. So this study demonstrated that signs and symptoms of infection 
or inflammation were mainly associated with severe neutropenia.   
 Also the National Comprehensive Cancer Network (NCCN®) highlighted that 
when cancer treatment caused neutropenia, this is considered as a serious condition since 
it could lead to infection especially when associated with fever. The usual conditions 
associated with severe neutropenia are hypotension, liver infection, kidney infection and 
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pneumonia. So NCCN guideline wrote that the signs associated with severe neutropenia 
were a result of infection (NCCN, 2006).    
                            
1.9.3  Neutropenia and Infection Types   
            When neutropenia or febrile neutropenia occur the patient will be at risk of 
infection either by gram-positive (G+ve) bacteria, gram-negative (G-ve) bacteria, fungal 
or even viral infection (Linker, 2000). About 60 % of the patients are infected with G+ve 
organisms which include Coagulaes-negative staphylococcus and Staphylococcus 
epidermis and 30% are infected with G-ve organisms such as Escherichia coli, Klebsiella 
spp. and Pseudomonas aeruginosa. While 10% of febrile neutropenic patients are 
infected by fungal infection such as Candida and Aspergillus (Flaherty, 1999).  Fungal 
infection is considered as a secondary infection however it could also become a primary 
infection if neutropenia persist for more than 10 days (Mitchell, 1999). Thus two blood 
cultures are needed for investigation that is one for bacteria and the other for fungal. 
These blood cultures should be taken one from the central venous catheter and the other 
from the peripheral vein (Mitchell, 1999). Bone aspiration and biopsy should also be 
taken in order to ascertain the main cause of the infection (Mitchell, 1999). Viral 
infection happens with neutropenic patient especially with recipients of bone marrow 
transplant. Usually these viruses include Herpes simplex, Cytomegalovirus virus and 
Varicella-zoster which is the most dangerous infection in neutropenic patient (Mitchell, 
1999). 
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1.9.3.1  Neutropenia and Bacterial Infection  
            The gram-negative (G-ve) bacterial infection has been the major and the 
predominant infection in the last 3 decades. During 1970s the G-ve infection represented 
60%-70% of the infections, while starting from the middle 1980s gram-positive (G+ve) 
became the major and predominant bacterial infection (Linker, 2000; Kimble-koda, et al., 
2002; Zinner, 1999; Sylvester, 2003).  
Table 1.1 show the types of bacteria that may cause infection in neutropenic patients. 
 
   Table 1.1: The types of bacteria that may cause infection in neutropenic patient 
   (Baskaran et al., 2007).   
 
Gram positive bacteria Gram negative bacteria 
1- Streptococcus species 
2- Coagulase-negative staphylococcus 
3- Enterococcus species  
4- Bacillus species  
5- Corynebacterium species 
1- Enterobacter species 
2- Escherichia coli 
3- Pseudomonas aeruginosa 
4- Klebsiella species 
5- Proteus mirabilis  
 
 
 
            There are many studies that have looked at bacterial infection in neutropenic 
patients which will be discussed below.   
            Firstly, a study was performed in Turkey by Gencer et al. (2003) on a total 
number of 177 neutropenic patients with median age of 55 years old (14 to 93 years). 
Ninety eight (98, 55%) of them were men and 79 (45%) of them were women. All of the 
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patients were suffering from neutropenia in different stages of severity and 67 of them 
were suffering from infection. Among the 67 patients with infection, 38 were diagnosed 
microbiologically while 29 were not. Most of the patients suffered from lower respiratory 
tract infection followed by urinary tract infection. The types of bacteria isolated were 
Escherichia coli (31%), Klebsiella pneumonia (18%), Pseudomonas aeruginosa (13%) 
and Streptococcus pneumoniae (13%). So this study showed that infection among the 
neutropenic patients was mostly caused by G –ve bacteria.     
            A second study was done by Maschmeyer and Hass (2007) in USA. This study 
suggested that the main factor that leads to mortality and morbidity among neutropenic 
patients was infection. They reported that since 1995 the predominant organism causing 
blood infection was gram-positive cocci bacteria, which increased from 62% to 72%. 
While the gram-negative bacilli infection decreased from 21.5% to 14% and the fungal 
infection decreased from 15% to 8%. They also suggested several factors that could lead 
to the increased in the gram-positive bacterial infection such as the high doses of 
chemotherapy (cytarabine), the used of oral nonabsorbable antibiotics and the used of 
proton pump inhibitors. Beside that severe mucosal damage of the gastrointestinal tract 
also put the neutropenic patients under the risk of gram-negative, gram-positive and 
candida infections.  
            Another study by Rolston (2005) focused on the factors that may increase the risk 
of bacterial infection. This study highlighted seven factors that could increase the risk of 
infection among neutropenic patients which are:  
1- The neutropenia duration and severity. 
2- The chemotherapeutic drug type and intensity. 
3- The patient’s condition.  
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4- The antibiotics effect.  
5- The central venous section catheter (CVSC) or other external device used.  
6- The characteristic of the surrounding environment for the patient. 
7- The prolonged period of hospital stay.  
 This study mentioned a very unique and important point which is the site of blood 
sampling taken for diagnosis of bacteria causing the infection. Since most of the studies 
depend only on blood stream culture this could lead to incorrect or incomplete picture for 
the type of bacterial infection. This is because only 15%-25% of the neutropenic patients 
develop bloodstream infections. While the other major sites for infections are the 
respiratory tract, skin, gastro intestinal tract (GIT) and the urinary tract. The major type 
of bacteria at these sites that could cause infection is the gram-negative bacteria, while in 
the blood stream the major type of bacterial causing infection is the gram-positive type. 
Another important focused of this study was the incidence of poly microbial infection. 
Neutropenic patient suffered from more than one infection and more than one bacterial 
type. Approximately 80% of the poly microbial infections contain a gram-negative 
bacteria. It was also reported that the percentage of gram-positive infection associated 
with mono microbial infection has declined from 75% to about 50%. Thus a new 
guideline was proposed whereby the entire bacterial infection spectrum must be obtained 
before starting empirical antibiotic treatment. Also in selecting the suitable empirical 
antibiotics, both blood stream culture test and biopsy results are needed.    
 
1.9.3.2  Neutropenia and Fungal Infection 
            The fungi kingdom is very large and contain more than 100,000 species but only 
200 species are responsible for infection in human (Dale, 2005). But unfortunately in the 
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last few years there are changes in the kind of the fungal infection and it has became 
dangerous and is considered as a life-threatening infection. This is especially of concern 
in patients who are really under continues danger of possibility being infected. These are 
patients with immunodeficiency virus (HIV), cancer patients (i.e., neutropenic patients), 
transplant recipients and patients on immune suppressive treatment (Richardson and 
Warnock, 2003). Fungal infection is usually slower than bacterial infection and usually 
occur by inhalation of spores or direct inoculation of the skin. Fungal infection usually 
occurs or takes place because of the overwhelming growth of the resident fungal 
population (Dale, 2005).      
                                                
1.9.3.3  Neutropenia and Viral Infection 
            Viral infection occurs frequently in people during their lives. It will usually cause 
an unpleasant feeling but has no serious dangerous effect on their lives except for cancer 
patients especially those who suffer from neutropenia. This is because of the weakness or 
defect in their immune system. The most predominant virus infecting cancer patients is 
Cytomegalovirus, while Herpes simplex virus (HSV) and Herpes zoster virus (HZV) are 
less frequent (Frey and Granger, 2005). 
                 
1.10  Neutropenia and Its Treatment 
1.10.1  Granulocyte Colony Stimulating Factors (G-CSF)   
            Colony stimulating factors (CSF’s) are glycoproteins which regulate the 
proliferation, differentiation, function activity and survival of myeloid cells. This will 
help in reducing the duration and severity of neutropenia as a result of chemotherapy use 
(Dale, 2004).    
